Praxis Precision Reports Negative Results from Monotherapy Aria Study in Patients with Major Depressive Disorder
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) has reported results from a Phase 2/3 Aria Study that evaluated the efficacy and safety of PRAX-114 for monotherapy treatment of major depressive disorder. It did not achieve statistical significance on the primary endpoint. ...